伊伐布雷定联合沙库巴曲缬沙坦治疗心力衰竭的临床效果

目的 探讨伊伐布雷定联合沙库巴曲缬沙坦治疗心力衰竭的临床效果.方法 选取2018年6月至2019年12月本院收治的42例心力衰竭患者作为研究对象,遵循随机原则将其分为参照组和研究组,各21例.参照组给予常规抗心力衰竭治疗,研究组给予伊伐布雷定联合沙库巴曲缬沙坦治疗.比较两组的临床疗效、不良反应发生情况、心功能指标、血清...

Clinical effect of ivabradine combined with sacubitril valsartan in the treatment of heart failure

Objective To investigate the clinical effect of ivabradine combined with sacubitril valsartan in the treatment of heart failure.Methods A total of 42 patients with heart failure treated in our hospital from June 2018 to December 2019 were selected as the research objects.The patients were divided into reference group and study group follow the random principle,with 21 cases in each group.The reference group was given conventional anti-heart failure treatment,and the study group was given ivabradine combined with sacubitril valsartan treatment.The clinical efficacy,occurrence of adverse reactions,cardiac function indexes,serological indexes level,immune function indexes and blood biochemical indexes level were compared between the two groups.Results The total effective rate of treatment in the study group was 95.24%,which was higher than 66.67%in the reference group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the study group was 4.76%,which was lower than 28.57%in the reference group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in SV,LVEF,LVESD,LVEDD and HR between the two groups(P>0.05);after treatment,SV and LVEF of the two groups were higher than those before treatment,LVESD,LVEDD and HR were lower than those before treatment,and those in the study group were better than the reference group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the NT-proBNP,ALD and ICAM-1 levels between the two groups(P>0.05);after treatment,the NT-proBNP,ALD and ICAM-1 levels in the two groups were lower than those before treatment,and those in the study group were lower than the reference group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the CD3⁺,CD4⁺/CD8⁺and IgM,IgA and IgG levels between the two groups(P>0.05);after treatment,the CD3⁺,CD4⁺/CD8⁺and IgM,IgA and IgG levels in the two groups were higher than those before treatment,and those in the study group were higher than the reference group,the differences were statistically significant(P<0.05).Before and after treatment,there were no significant differences in the blood potassium,blood sodium and blood creatinine levels between the two groups(P>0.05).Conclusion Ivabradine combined with sacubitril valsartan in the treatment of heart failure has a significant effect,which can reduce the incidence of adverse reactions,improve cardiac function and immune function,and reduce the serological indexes level.It is worthy of clinical promotion and application.